 Shannon Carpenter
Concepts (196)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hemophilia A | 13 | 2023 | 15 | 4.380 |
Why?
| | Venous Thromboembolism | 5 | 2018 | 13 | 2.670 |
Why?
| | Thrombosis | 6 | 2023 | 15 | 2.350 |
Why?
| | Child Abuse | 10 | 2022 | 46 | 2.220 |
Why?
| | Factor VIII | 8 | 2023 | 8 | 1.890 |
Why?
| | Humans | 52 | 2023 | 6896 | 1.860 |
Why?
| | Blood Coagulation Disorders | 6 | 2022 | 8 | 1.850 |
Why?
| | Contusions | 5 | 2022 | 8 | 1.730 |
Why?
| | Child | 34 | 2023 | 3364 | 1.550 |
Why?
| | Hemorrhage | 8 | 2022 | 19 | 1.360 |
Why?
| | Blood Coagulation Disorders, Inherited | 3 | 2020 | 3 | 1.350 |
Why?
| | Female | 25 | 2023 | 3525 | 1.250 |
Why?
| | Child, Preschool | 21 | 2023 | 1569 | 1.120 |
Why?
| | Male | 23 | 2023 | 3337 | 1.100 |
Why?
| | Retrospective Studies | 15 | 2023 | 1296 | 0.990 |
Why?
| | Purpura, Thrombotic Thrombocytopenic | 1 | 2023 | 1 | 0.920 |
Why?
| | Hemostatics | 1 | 2023 | 3 | 0.920 |
Why?
| | Adolescent | 20 | 2023 | 2197 | 0.900 |
Why?
| | Upper Extremity Deep Vein Thrombosis | 1 | 2023 | 2 | 0.880 |
Why?
| | Venous Thrombosis | 1 | 2023 | 2 | 0.880 |
Why?
| | Central Venous Catheters | 1 | 2023 | 5 | 0.880 |
Why?
| | Blood Coagulation Tests | 4 | 2019 | 4 | 0.870 |
Why?
| | Catheterization, Central Venous | 1 | 2023 | 18 | 0.870 |
Why?
| | Antibodies, Bispecific | 1 | 2022 | 1 | 0.830 |
Why?
| | Anticoagulants | 2 | 2019 | 20 | 0.770 |
Why?
| | Pulmonary Embolism | 2 | 2018 | 3 | 0.760 |
Why?
| | Nephrotic Syndrome | 2 | 2018 | 29 | 0.760 |
Why?
| | Craniocerebral Trauma | 4 | 2021 | 18 | 0.730 |
Why?
| | Factor V Deficiency | 1 | 2019 | 1 | 0.700 |
Why?
| | Factor V | 1 | 2019 | 3 | 0.700 |
Why?
| | Diagnosis, Differential | 10 | 2022 | 77 | 0.690 |
Why?
| | Blood | 1 | 2019 | 10 | 0.680 |
Why?
| | Risk Factors | 6 | 2023 | 487 | 0.680 |
Why?
| | Hemorrhagic Disorders | 3 | 2014 | 4 | 0.680 |
Why?
| | Heart Defects, Congenital | 2 | 2017 | 81 | 0.670 |
Why?
| | Mechanical Thrombolysis | 1 | 2019 | 1 | 0.660 |
Why?
| | Enoxaparin | 1 | 2019 | 3 | 0.660 |
Why?
| | Thromboembolism | 1 | 2019 | 3 | 0.660 |
Why?
| | Databases, Factual | 3 | 2018 | 108 | 0.650 |
Why?
| | Pneumococcal Infections | 1 | 2018 | 6 | 0.640 |
Why?
| | Streptococcus pneumoniae | 1 | 2018 | 5 | 0.640 |
Why?
| | Immune Tolerance | 1 | 2018 | 8 | 0.630 |
Why?
| | Infant | 16 | 2021 | 1446 | 0.620 |
Why?
| | Cardiac Surgical Procedures | 1 | 2017 | 30 | 0.590 |
Why?
| | United States | 8 | 2023 | 669 | 0.580 |
Why?
| | Factor VII Deficiency | 1 | 2017 | 3 | 0.580 |
Why?
| | Genitalia, Female | 1 | 2017 | 4 | 0.580 |
Why?
| | Infant, Newborn | 8 | 2023 | 816 | 0.560 |
Why?
| | Isoantibodies | 2 | 2015 | 8 | 0.530 |
Why?
| | Staphylococcus aureus | 1 | 2015 | 18 | 0.520 |
Why?
| | Staphylococcal Infections | 1 | 2015 | 21 | 0.520 |
Why?
| | Bacteremia | 1 | 2015 | 25 | 0.510 |
Why?
| | Hepatitis B Vaccines | 1 | 2014 | 2 | 0.490 |
Why?
| | Adult | 10 | 2023 | 1181 | 0.490 |
Why?
| | Data Collection | 1 | 2014 | 29 | 0.490 |
Why?
| | Platelet Storage Pool Deficiency | 1 | 2013 | 1 | 0.460 |
Why?
| | Thrombophilia | 1 | 2013 | 2 | 0.450 |
Why?
| | Polymorphism, Genetic | 2 | 2013 | 90 | 0.420 |
Why?
| | Plasma | 2 | 2023 | 7 | 0.400 |
Why?
| | Young Adult | 6 | 2023 | 647 | 0.380 |
Why?
| | Intracranial Hemorrhages | 4 | 2018 | 7 | 0.380 |
Why?
| | Inpatients | 2 | 2022 | 44 | 0.360 |
Why?
| | Vitamin K Deficiency | 1 | 2009 | 1 | 0.340 |
Why?
| | Antifibrinolytic Agents | 1 | 2009 | 3 | 0.340 |
Why?
| | Vitamin K | 1 | 2009 | 5 | 0.340 |
Why?
| | Midwifery | 1 | 2009 | 2 | 0.340 |
Why?
| | Logistic Models | 3 | 2018 | 84 | 0.340 |
Why?
| | Glucuronosyltransferase | 1 | 2008 | 16 | 0.320 |
Why?
| | Gallbladder Diseases | 1 | 2008 | 12 | 0.320 |
Why?
| | Anemia, Sickle Cell | 1 | 2008 | 17 | 0.320 |
Why?
| | Promoter Regions, Genetic | 1 | 2008 | 49 | 0.320 |
Why?
| | Cohort Studies | 4 | 2020 | 289 | 0.300 |
Why?
| | Radioisotopes | 2 | 2017 | 2 | 0.300 |
Why?
| | Hemostasis | 3 | 2023 | 3 | 0.290 |
Why?
| | von Willebrand Factor | 2 | 2023 | 2 | 0.280 |
Why?
| | Cross-Sectional Studies | 3 | 2020 | 336 | 0.280 |
Why?
| | Prevalence | 4 | 2022 | 146 | 0.270 |
Why?
| | Recurrence | 2 | 2018 | 110 | 0.260 |
Why?
| | von Willebrand Diseases | 2 | 2022 | 4 | 0.250 |
Why?
| | Practice Guidelines as Topic | 2 | 2017 | 108 | 0.250 |
Why?
| | Anemia, Dyserythropoietic, Congenital | 1 | 2004 | 1 | 0.230 |
Why?
| | Parvoviridae Infections | 1 | 2004 | 1 | 0.230 |
Why?
| | Parvovirus B19, Human | 1 | 2004 | 1 | 0.230 |
Why?
| | Spherocytosis, Hereditary | 1 | 2004 | 3 | 0.230 |
Why?
| | ADAM Proteins | 1 | 2023 | 1 | 0.230 |
Why?
| | Catheters | 1 | 2023 | 4 | 0.220 |
Why?
| | Follow-Up Studies | 1 | 2023 | 304 | 0.210 |
Why?
| | Length of Stay | 3 | 2018 | 233 | 0.210 |
Why?
| | Minor Surgical Procedures | 1 | 2022 | 1 | 0.210 |
Why?
| | Injections, Intramuscular | 2 | 2014 | 5 | 0.210 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2022 | 34 | 0.200 |
Why?
| | Intracranial Thrombosis | 1 | 2021 | 3 | 0.190 |
Why?
| | North America | 2 | 2018 | 44 | 0.190 |
Why?
| | Retinoschisis | 1 | 2021 | 1 | 0.190 |
Why?
| | Range of Motion, Articular | 2 | 2017 | 8 | 0.190 |
Why?
| | Point-of-Care Systems | 1 | 2020 | 10 | 0.180 |
Why?
| | Hemarthrosis | 2 | 2017 | 2 | 0.180 |
Why?
| | Decision Support Systems, Clinical | 1 | 2020 | 17 | 0.180 |
Why?
| | Referral and Consultation | 2 | 2022 | 32 | 0.170 |
Why?
| | Electronic Health Records | 1 | 2020 | 64 | 0.170 |
Why?
| | Acute Disease | 2 | 2013 | 79 | 0.170 |
Why?
| | Treatment Outcome | 2 | 2019 | 622 | 0.170 |
Why?
| | Transitional Care | 1 | 2018 | 3 | 0.160 |
Why?
| | Intensive Care Units | 1 | 2018 | 17 | 0.160 |
Why?
| | Guidelines as Topic | 1 | 2018 | 11 | 0.160 |
Why?
| | Heparin, Low-Molecular-Weight | 1 | 2018 | 1 | 0.160 |
Why?
| | Heparin | 1 | 2018 | 6 | 0.160 |
Why?
| | Child, Hospitalized | 1 | 2018 | 26 | 0.160 |
Why?
| | Patient Readmission | 1 | 2018 | 68 | 0.150 |
Why?
| | Survival Analysis | 1 | 2017 | 50 | 0.150 |
Why?
| | Patient Outcome Assessment | 1 | 2017 | 8 | 0.150 |
Why?
| | Synovitis | 1 | 2017 | 1 | 0.150 |
Why?
| | Middle Aged | 5 | 2018 | 608 | 0.150 |
Why?
| | Hospitals, Pediatric | 2 | 2022 | 187 | 0.150 |
Why?
| | Body Mass Index | 1 | 2017 | 157 | 0.140 |
Why?
| | Prospective Studies | 3 | 2023 | 525 | 0.140 |
Why?
| | Ascorbic Acid | 1 | 2016 | 1 | 0.140 |
Why?
| | Scurvy | 1 | 2016 | 1 | 0.140 |
Why?
| | Virulence Factors | 1 | 2015 | 4 | 0.130 |
Why?
| | Veterans | 1 | 2015 | 2 | 0.130 |
Why?
| | C-Reactive Protein | 1 | 2015 | 16 | 0.130 |
Why?
| | Hemoglobins | 1 | 2015 | 27 | 0.130 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2015 | 16 | 0.130 |
Why?
| | Autism Spectrum Disorder | 1 | 2016 | 32 | 0.130 |
Why?
| | Intimate Partner Violence | 1 | 2015 | 16 | 0.130 |
Why?
| | Acute Kidney Injury | 1 | 2015 | 30 | 0.130 |
Why?
| | Pneumonia, Aspiration | 1 | 2015 | 8 | 0.130 |
Why?
| | Menstruation | 1 | 2015 | 4 | 0.130 |
Why?
| | Menorrhagia | 1 | 2015 | 4 | 0.130 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2015 | 39 | 0.120 |
Why?
| | Hepatitis B Antibodies | 1 | 2014 | 1 | 0.120 |
Why?
| | Hematology | 1 | 2014 | 3 | 0.120 |
Why?
| | Injections, Subcutaneous | 1 | 2014 | 8 | 0.120 |
Why?
| | Practice Patterns, Physicians' | 2 | 2014 | 85 | 0.120 |
Why?
| | Vaccination | 1 | 2014 | 71 | 0.120 |
Why?
| | Genome-Wide Association Study | 1 | 2015 | 190 | 0.120 |
Why?
| | Wounds and Injuries | 1 | 2014 | 38 | 0.120 |
Why?
| | Antiphospholipid Syndrome | 1 | 2013 | 1 | 0.110 |
Why?
| | Hospitalization | 1 | 2015 | 210 | 0.110 |
Why?
| | Risk Assessment | 1 | 2013 | 137 | 0.110 |
Why?
| | Coagulants | 1 | 2012 | 1 | 0.100 |
Why?
| | Pediatrics | 1 | 2014 | 186 | 0.100 |
Why?
| | Blood Coagulation Factors | 1 | 2011 | 1 | 0.100 |
Why?
| | Medication Adherence | 1 | 2012 | 21 | 0.100 |
Why?
| | Retinal Hemorrhage | 2 | 2021 | 2 | 0.100 |
Why?
| | Neoplasms | 1 | 2013 | 128 | 0.090 |
Why?
| | Aged | 3 | 2017 | 378 | 0.090 |
Why?
| | Hematoma, Subdural | 2 | 2021 | 4 | 0.090 |
Why?
| | Brain Death | 1 | 2009 | 3 | 0.080 |
Why?
| | Texas | 1 | 2009 | 20 | 0.080 |
Why?
| | Hyperbilirubinemia | 1 | 2008 | 8 | 0.080 |
Why?
| | Bilirubin | 1 | 2008 | 26 | 0.080 |
Why?
| | Multicenter Studies as Topic | 1 | 2008 | 19 | 0.080 |
Why?
| | Longitudinal Studies | 1 | 2008 | 119 | 0.080 |
Why?
| | Reproducibility of Results | 1 | 2008 | 199 | 0.080 |
Why?
| | Alleles | 1 | 2008 | 214 | 0.070 |
Why?
| | Aged, 80 and over | 2 | 2017 | 151 | 0.070 |
Why?
| | Genetic Variation | 1 | 2008 | 174 | 0.070 |
Why?
| | Tomography, X-Ray Computed | 2 | 2015 | 117 | 0.060 |
Why?
| | Erythroid Precursor Cells | 1 | 2004 | 2 | 0.060 |
Why?
| | Hyperplasia | 1 | 2004 | 5 | 0.060 |
Why?
| | Age Factors | 2 | 2015 | 210 | 0.060 |
Why?
| | Anxiety Disorders | 1 | 2022 | 19 | 0.050 |
Why?
| | Anxiety | 1 | 2022 | 51 | 0.050 |
Why?
| | Consensus | 1 | 2022 | 35 | 0.050 |
Why?
| | Communication | 1 | 2022 | 46 | 0.050 |
Why?
| | Depression | 1 | 2022 | 69 | 0.050 |
Why?
| | Quality of Life | 1 | 2022 | 140 | 0.050 |
Why?
| | Retina | 1 | 2021 | 5 | 0.050 |
Why?
| | North Carolina | 1 | 2018 | 3 | 0.040 |
Why?
| | Registries | 1 | 2017 | 92 | 0.040 |
Why?
| | Mental Health Services | 1 | 2015 | 2 | 0.030 |
Why?
| | Needs Assessment | 1 | 2015 | 18 | 0.030 |
Why?
| | Health Services Needs and Demand | 1 | 2015 | 15 | 0.030 |
Why?
| | Medical Records | 1 | 2015 | 14 | 0.030 |
Why?
| | Odds Ratio | 1 | 2015 | 51 | 0.030 |
Why?
| | Linear Models | 1 | 2015 | 56 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2015 | 71 | 0.030 |
Why?
| | Incidence | 1 | 2015 | 133 | 0.030 |
Why?
| | Hormones | 1 | 2015 | 3 | 0.030 |
Why?
| | Critical Illness | 1 | 2015 | 22 | 0.030 |
Why?
| | Menarche | 1 | 2015 | 4 | 0.030 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2015 | 38 | 0.030 |
Why?
| | Time Factors | 1 | 2015 | 250 | 0.030 |
Why?
| | Observational Studies as Topic | 1 | 2014 | 3 | 0.030 |
Why?
| | Vitamin K Deficiency Bleeding | 1 | 2013 | 1 | 0.030 |
Why?
| | Decision Support Techniques | 1 | 2013 | 6 | 0.030 |
Why?
| | Medical Audit | 1 | 2012 | 1 | 0.030 |
Why?
| | Health Surveys | 1 | 2012 | 15 | 0.030 |
Why?
| | Infusions, Intravenous | 1 | 2012 | 26 | 0.030 |
Why?
| | Urban Population | 1 | 2012 | 27 | 0.030 |
Why?
| | Statistics, Nonparametric | 1 | 2011 | 17 | 0.030 |
Why?
| | Missouri | 1 | 2012 | 81 | 0.020 |
Why?
| | Cross-Over Studies | 1 | 2011 | 35 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2011 | 35 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2012 | 274 | 0.020 |
Why?
|
|
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|